IgGenix uses a proprietary single-cell RNA-sequencing platform, SEQ SIFTER™, to isolate and engineer fully human, high-affinity IgG antibodies that target immunodominant allergens, blocking the allergic cascade. This approach aims to develop safe, injectable therapies for food and environmental allergies, with the first candidate, IGNX001, currently in Phase 1 trials for peanut allergy.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Current allergy therapies often provide temporary relief or require lifelong management, failing to address the underlying cause of allergic reactions. Existing treatments may also carry the risk of adverse side effects or limited efficacy across diverse patient populations. There remains a need for targeted therapies that can durably block the allergic cascade and prevent severe reactions.
Solution
IgGenix is developing a new class of fully human IgG antibodies designed to target and neutralize immunodominant allergens, thereby preventing the allergic cascade. The company's SEQ SIFTER™ platform enables the isolation and engineering of high-affinity antibodies specific to IgE-mediated allergic responses. By focusing on common immunodominant epitopes, IgGenix aims to create therapies that can effectively treat a broad range of patients with food and environmental allergies. Their lead candidate, IGNX001, is currently in Phase 1 clinical trials for peanut allergy, with additional programs in discovery and preclinical stages for other food allergies, atopic dermatitis, and autoimmune conditions.
Target Audience
The primary target audience includes individuals with severe food and environmental allergies, as well as those suffering from atopic dermatitis and other IgE-mediated immunological diseases.
Features
- SEQ SIFTER™ single-cell RNA-sequencing platform for isolating rare, allergen-specific IgE-producing B cells
- Antibody engineering to generate fully human, high-affinity IgG antibodies that block IgE binding
- Identification of immunodominant epitopes to target the most common triggers of allergic reactions
- Pipeline of therapeutic candidates for food allergies (peanut, egg, milk, etc.) and environmental allergies (cat, dog, pollen, etc.)
- Preclinical research programs in atopic dermatitis and other IgE-mediated immunological diseases
- IGNX001, a first-in-class antibody therapeutic for peanut allergy, currently in Phase 1 clinical trials